Objective To analyze the risk factors of progressive urinary incontinence in female patients with pelvic floor organ prolapse (pop) after pelvic floor reconstruction

and to construct its risk prediction model

so as to provide a clinical tool for predicting postoperative progressive SUI. Methods From May

2019 to April

2022

patients with pelvic floor organ prolapse with ICS-POP Q score ≥II

who underwent pelvic floor reconstruction in Yijishan Hospital of Wannan Medical College for 6 months

were retrospectively analyzed. The general clinical data and preoperative pelvic floor ultrasound results of 495 patients were collected and followed up. According to the occurrence of SUI before and after operation

it was divided into SUI improvement group and progressive group (including new and aggravated cases). Univariate and multivariate Logistic regression analysis was adopted

and the risk prediction model of progressive SUI after operation was established

and internal verification was carried out. R software rms package was used to construct its risk Nomogram. Results In this study

76 patients developed progressive SUI after operation. Positive SUI in preoperative acupressure test

low position of Ba point indicated by POP-Q score

formation of small funnel in urethral orifice by pelvic floor ultrasound and levator ani avulsion are independent risk factors for postoperative progressive SUI. Combining the above four parameters

a model Logit P was established

with 0.515 as the cutoff value. The C- statistic of the model was 0.885(95%CI 0.737~0.936)

and the Jordan index was 0.936. Sensitivity is 0.936

specificity is 0.737

positive likelihood ratio is 3.557

negative likelihood ratio is 0.087

diagnostic ratio is 40.885

positive predictive value is 0.911

negative predictive value is 0.800. Conclusion In this study

the Nomogram chart for predicting the risk of progressive SUI after pelvic floor reconstruction was finally established

which has a good prediction effect and provides clinical value for preoperative treatment of POP patients.